BioLife Solutions, Inc. (Formerly Cryomedical Sciences)

223 articles about BioLife Solutions, Inc. (Formerly Cryomedical Sciences)

• BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank

  3/10/2023

  BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, provided commentary on its current banking relationship with Silicon Valley Bank.

• BioLife Sciences Inc. (OTC: BLFE) Announces Letter of Intent for Exclusive Licensing Deal with Canadian Firm

  2/2/2023

  BioLife Sciences is pleased to announce that it has entered into a non-binding letter of intent dated February 01, 2023 with Canadian Company–Work In Motion pursuant to which the parties will complete an exclusive licensing agreement for the development and commercialization of custom designed copper infused bamboo gardening gloves.

• BioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work For

  1/10/2023

  BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy and the broader biopharma markets, announced that the Company was recently named as one of Seattle Business magazine's Washington's Best Companies to Work for.

• BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023

  12/19/2022

  BioLife Solutions, Inc. (NASDAQ: BLFS) today announced plans to announce preliminary 2022 revenue and introduce 2023 revenue guidance before market open on January 9, 2023, in advance of management's meetings with investors, customers, and partners concurrent with the 41st Annual J.P. Morgan Health Care Conference in San Francisco January 9-12.

• BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022

  11/2/2022

  BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2022 financial results will be released after market close on Wednesday, November 9th.

• BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022

  8/2/2022

  BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9th.

• BioLife Sciences Inc. Files Form 1-A with the Securities and Exchange Commission (SEC) to Raise Capital Under a Tier I Regulation A+ Offering

  6/1/2022

  via NewMediaWire – BioLife Sciences Inc., announced that it has filed Form 1-A with the Securities and Exchange Commission seeking to raise up to $20 million under a Tier I Regulation A+ offering.

• BioLife Solutions Reports First Quarter 2022 Financial Results

  5/9/2022

  BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2022.

• BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K

  3/17/2022

  BioLife Solutions, Inc. announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the "Form 10-K").

• BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing

  1/4/2022

  BioLife Solutions, Inc. (NASDAQ: BLFS), today announced an extended collaboration with Seattle Children's Therapeutics, a venture at Seattle Children's, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children.

• BioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer

  4/15/2021

  BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company.

• BioLife Sciences (OTCPK:BLFE) Initiates Process for Up-Listing to OTCQB

  11/9/2020

  BioLife Sciences Inc. (OTCPK:BLFE) announces it has initiated the process of up-listing to the Over the Counter Quotation Bureau (“OTCQB®”) by engaging MNP LLP (“MNP”), an accounting firm registered with the U.S Public Company Accounting Oversighting Board (“PCAOB”), to independently audit BioLife’s finances.

• Biolife Sciences (OTCPK: BLFE) Announces Agreement to Provide Aircraft Cleaning and Disinfecting Services for the Transportation & Travel Sector

  11/2/2020

  BioLife Sciences (OTCPK: BLFE) has entered into an agreement with FLYGTA to become the exclusive supplier of electrostatic disinfection and cleaning services for their commercial airplane fleet using an innovative antimicrobial treatment system.

• BioLife Sciences Inc. (BLFE) Offers Non-Contact Human Temperature Screening Technology

  10/5/2020

  BioLife Sciences Inc. (OTC Markets: BLFE) is introducing non-contact human temperature screening to its lineup of products designed to provide businesses with cost-effective solutions to successfully navigate through the current health crisis. BioLife Sciences’ non-contact human temperature screening technology offers state-of-the-art, intelligent thermal imaging technology. The AI Screening Technology can measure temperature and

• BioLife Solutions to Join Russell Microcap® Index

  6/11/2018

  BioLife Solutions, Inc. announced that it is set to join the Russell Microcap® Index at the conclusion of the Russell US Indexes annual reconstitution,

• BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results

  3/8/2018

  BioLife Solutions, Inc. reported financial results and operational highlights for the three and 12 months ended December 31, 2017.

• BioLife Solutions Announces SAVSU Alliance With World Courier

  1/23/2018

  The combination of World Courier's global logistics network and SAVSU's patent pending.

• SAVSU Technologies and BioLife Solutions Increase evo Intellectual Property Estate with Notice of Allowance of New Patent for Cold Chain Technologies

  1/18/2018

  The inventors are Bruce McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions.

• BioLife Solutions Executes Additional Long-Term Supply Agreement with Leading T Cell Therapy Customer

  11/29/2017

  BioLife Solutions today announced that it has executed a new confidential agreement to supply its proprietary CryoStor cell freeze media to a leading T cell therapy customer.

• BioLife Solutions Announces Third Quarter 2017 Financial Results

  11/10/2017

  Revenue from biopreservation media product sales for the third quarter of 2017 was a new record of $3M, an increase of 39% compared with the third quarter of 2016.